- Home
- FRGE vs RIGL Comparison
FRGE vs RIGL Comparison
Compare FRGE & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FRGE | RIGL |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 615.4M | 537.6M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | FRGE | RIGL |
|---|---|---|
| Price | $44.57 | $41.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $31.00 | ★ $43.20 |
| AVG Volume (30 Days) | 451.9K | ★ 526.2K |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | N/A | ★ 6.20 |
| Revenue | $92,884,000.00 | ★ $282,076,000.00 |
| Revenue This Year | $33.10 | $65.53 |
| Revenue Next Year | $24.07 | $0.22 |
| P/E Ratio | ★ N/A | $6.74 |
| Revenue Growth | 16.40 | ★ 79.13 |
| 52 Week Low | $6.60 | $14.63 |
| 52 Week High | $44.76 | $52.24 |
Technical Indicators
Market Signals| Indicator | FRGE | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 85.45 | 49.03 |
| Support Level | $44.30 | $40.52 |
| Resistance Level | $44.75 | $43.58 |
| Average True Range (ATR) | 0.14 | 2.73 |
| MACD | -0.75 | -0.88 |
| Stochastic Oscillator | 67.27 | 21.72 |
Price Performance
Historical ComparisonAbout FRGE Forge Global Holdings Inc.
Forge Global Holdings Inc is a financial service platform created to serve the needs of the private market. It provides marketplace infrastructure, data services, and technology solutions for private market participants. The company offers a trusted trading platform, proprietary data and insights to inform investment strategies, along with custody services to help companies, shareholders, institutions and accredited investors confidently navigate and transact in the private market.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.